サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1133469

ゲムシタビンHCLの世界市場-2022-2029

Global Gemcitabine HCL Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 250 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
ゲムシタビンHCLの世界市場-2022-2029
出版日: 2022年10月11日
発行: DataM Intelligence
ページ情報: 英文 250 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

ゲムシタビンHCLの市場成長は、高齢者人口の増加、がん疾患の増加、技術の進歩、治療法を改善するための研究活動など、いくつかの要因に牽引されています。

がん疾患の蔓延が市場成長の原動力となる見込み

乳がんや膵臓がんなどの増加により、ゲムシタビンHCLの需要が世界的に高まっています。世界保健機関（WHO）によると、がんは世界的に主要な死因となっています。2020年の死亡者数は約1,000万人で、患者の6人に1人ががんで死亡するといわれています。最も一般的ながんは、乳がん、肺がん、結腸がん、直腸がん、前立腺がんです。がんによる死亡の約3分の1は、高い肥満度、アルコール摂取、タバコの使用、野菜や果物の摂取量の少なさ、運動不足が原因となっています。2022年2月のWHOのデータによると、2020年には世界で乳がんが226万人、肺がんが221万人、皮膚がんが120万人、結腸・直腸がんが193万人になると言われています。また、毎年、40万人の子どもががんを発症しています。がんの中で最も多いのは子宮頸がんです。がん疾患の発症率は年齢とともに上昇しますが、その原因の多くは、特定のがんの危険因子が年齢とともに蓄積されることにあります。がん患者を治療するためには、がんを適時に診断することが必要です。多くのがんは、早期に発見し、効果的な治療を行えば完治させることができます。治療法の適切な選択においては、がんと個人の両方を考慮した上で治療が行われます。ゲムシタビンHCLは静脈注射で投与され、代謝拮抗薬と呼ばれる薬剤群に属し、細胞内の正常な物質と非常によく似ています。これは、細胞周期に特異的です。細胞がこの物質を細胞代謝に取り込むと、細胞分裂ができなくなります。主に、DNA合成中のがん細胞のプログラム細胞死を促進することで、抗腫瘍効果を発揮します。具体的には、G1/S-phaseの境界を通過する細胞の進行を阻害します。そうして細胞分裂を防ぎ、さまざまながんを予防するのです。

ゲムシタビンHCLの副作用が市場成長の妨げとなる

しかし、ゲムシタビンHCLの副作用として、異常な脱力感、食欲不振、濃い尿、腕や肩に広がる痛み、突然の激しい頭痛発熱、悪寒、体の痛み、インフルエンザ症状、聴覚障害、呼吸障害、胸の痛みと重い感じなどが研究で示されています。これらの副作用は、患者の健康リスクを生じさせ、市場の成長に悪影響を及ぼす可能性があります。

COVID-19の影響分析

COVID-19の出現は、その抗ウイルス作用により、これらの薬剤の世界の需要にかなりの影響を及ぼしました。新型ウイルスがヒトの病原体として大流行するのを防ぐには、公衆衛生専門家が感染を診断し、その拡大を抑制し、その原因を治療することが不可欠です。例えば、ゲムシタビンは抗ウイルス作用を有することから、MERS-CoVやSARS-CoV感染症などの後続のウイルス性疾患の治療経験を踏まえ、COVID-19感染症の治療に使用する可能性のある薬剤リストにまとめられています。塩酸ゲムシタビンは、そのためのヌクレオシドアナログ阻害剤の一つです。SARS-CoV-2治療薬として有効です。このため、市場では感染症治療薬として高い需要があります。コロナウイルスの感染者が世界的に増加するにつれて、需要が世界的に増加しています。例えば、2022年9月のWHOのデータ報告によると、コロナウイルスの確定症例は世界で609,848,852人となっています。

一方、パンデミック時には、輸送制限や封鎖により、多くの患者が通常の治療を受けることが困難な状況に陥りました。しかし、2021年ではなく2022年半ばに逆転しているため、病院での治療が受けられるようになりました。この市場も予測期間には良好な成長を見せるでしょう。

世界のゲムシタビンHCL市場レポートでは、約55以上の市場データ表、50以上の図、250ページ（概算）の範囲でのアクセスを提供することになります。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • アプリケーション別市場内訳
  • エンドユーザー別市場内訳
  • 流通チャネル別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 老年人口の増加
      • 癌疾患の増加
    • Restraints
    • ゲムシタビンHCLの副作用
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制当局の分析
  • 疫学

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 アプリケーション別

  • 膵臓がん
  • 非小細胞肺がん
  • 膀胱癌
  • 軟部肉腫
  • 転移性乳がん
  • 卵巣癌

第8章 エンドユーザー別

  • 病院
  • 在宅医療
  • 専門施設
  • その他

第9章 流通チャネル別

  • 病院内薬局
  • オンライン薬局
  • 小売店

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク

第12章 企業プロファイル

  • Eli Lilly and Company
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Teva Pharmaceutical Industries Ltd.
  • Accord-UK Ltd.
  • Pfizer, Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories Ltd.
  • Ingenus Pharmaceuticals
  • NuCana Biomed's

第13章 ゲムシタビンHCLの世界市場-DataM

目次
Product Code: DMPH5860

Market Overview

Gemcitabine HCL Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of X% during the forecast period (2022-2029).

Gemcitabine HCL is an FDA-approved drug with antineoplastic activity. It can be taken as a stand-alone or with other drugs. It is used for breast cancer, non-small cell cancer, ovarian cancer, pancreatic cancer, and others. This medication is given to the patient by injection into a vein by healthcare professionals. The dosage is based on the patient's medical condition, body size, and response to treatment.

Market Dynamics

The gemcitabine HCL market growth is driven by several factors, such as an increase in the geriatric population, an increase in cancer diseases, technological advancements, and research activities for improvising the treatment.

The prevalence of cancer disease is expected to drive the market growth

The rise in breast cancer, pancreatic cancer, and many more is increasing the demand for gemcitabine HCL globally. According to the World Health Organization (WHO), cancer is the main cause of death globally. Approximately 10 million deaths in 2020 will be due to cancer, or nearly one in six deaths of patients. The most common cancers are breast, lung, colon, rectum, and prostate cancers. Around one-third of all cancer deaths are due to high body mass index, alcohol consumption, tobacco use, low vegetable, and fruit intake, and lack of physical activity. According to WHO data from February 2022, in 2020, there will be 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.20 million cases of skin cancer, and 1.93 million cases of colon and rectum cancer worldwide. In addition, every year, 400,000 children develop cancer. Cervical cancer is the most common cancer. The incidence of cancer disease increases with age, mostly due to risk factors building up for specific cancers that rise with age. To treat a cancer patient, it is necessary to diagnose cancer on time. Many cancers can be cured if detected early and treated effectively. In the proper selection of treatment, both cancer and the individual are considered for treatment. Gemcitabine HCL is given intravenously and belongs to a family of drugs called antimetabolites, which are very similar to normal substances within the cell. It is cell-cycle specific. When the cells incorporate these substances into the cellular metabolism, they are unable to divide. Mainly, it shows anitumor effects by promoting programmed cell death of cancer cells undergoing DNA synthesis. Specifically it blocks progression of cells through the G1/S-phase boundary. That's how it prevents the division of cells and prevents different cancers.

The side effects of gemcitabine HCL will hamper the growth of the market

However, studies have shown side effects of gemcitabine HCL, such as unusual weakness, loss of appetite, dark urine, pain spreading to the arm or shoulder, sudden severe headache fever, chills, body aches, flu symptoms, hearing problems, breathing problems, and chest pain and heavy feeling. These side effects create health risks among patients, which may adversely affect the market's growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global demand for these drugs due to their antiviral activity. In order to prevent the novel virus from rising into a pandemic human pathogen, it is essential that public health professionals can diagnose the infection, control its spread, and treat its causes. For instance, due to the antiviral activity of gemcitabine, HCL is compiled in the list of drugs with the potential to be used in the treatment of COVID-19 infection based on experience in treating a subsequence of viral diseases such as MERS-CoV and SARS-CoV infection. Gemcitabine hydrochloride is one of the nucleoside analog inhibitors for this purpose. It is valid for the treatment of SARS-CoV-2 treatment. Due to this, the demand is high in the market to treat the infection. As the cases of coronavirus rise worldwide, the demand has increased worldwide. For instance, as per the WHO data report of September 2022, the confirmed cases of coronaviruses are 609,848,852 globally.

On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Segment Analysis

The pancreas cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pancreatic cancer segment is expected to hold the dominant market share over the period forecast (2022-2029). Pancreatic cancer is one of the cancers with high mortality and has a common survival rate of 6-8%. In recent years, cancer has been proven to be one of the deadliest in the United States, with high morbidity, typically in elderly patients. Nowadays, there exists a large unmet need for drugs and drug delivery vehicles that can provide excellent therapeutic advantages. Substantial interest in Gemcitabine as a combination therapy is gathering among researchers. An increasing body of studies on its pharmacology has propelled the revenue potential of key players in this segment. Furthermore, pancreatic cancer accounts for 8% of male deaths and 8% of female deaths in the United States, according to the American Cancer Society. In the United States, new cancer cases occur in 3% of males and 3% of females. In addition, more than 90% of cases develop in the exocrine tissue of the pancreas, which helps enzymes digest food. The less common endocrine tumors, mainly referred to as pancreatic neuroendocrine tumours (NETs), develop in hormone-producing cells and have a younger median age at diagnosis and better prediction.

Geographical Analysis

North America region holds the largest market share of the global gemcitabine HCL market

North America dominates the market for gemcitabine HCL and is expected to show a similar trend over the forecast period owing to the increased geriatric population, advanced healthcare infrastructure, increased incidences of cancer diseases, and favorable government initiatives. As per the American Cancer Society, Inc., 2022 report, nearly 1.9 million new cases are anticipated to be diagnosed in the U.S. alone, and there are 609,360 cancer deaths in the United States due to cancer. As we increase in age, there is a risk of developing cancer. 80% of the population diagnosed with cancer in the US is 55 years of age or older, and 57% are 65 or older due to certain behaviors such as drinking alcohol, eating habits, smoking, and having excess body weight. In addition, in the United States, it is estimated that 40 out of 100 men and 39 out of 100 women will develop cancer during their life span. With the increased number of cancer cases, there is more demand for gemcitabine HCL in the market to treat different cancers in patients.

Competitive Landscape

The gemcitabine HCL market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy's Laboratories Ltd., Ingenus Pharmaceuticals and NuCana Biomed's among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the gemcitabine HCL market globally.

For instance,

  • In September 2022, NuCana plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1031), derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. It is currently evaluated in a Phase III study for the first-line treatment of patients with advanced biliary tract cancer.

Stryker Corporation

Overview:

Eli Lilly and Company is an American pharmaceutical company headquartered in Indiana, founded in 1876, with a presence in 18 countries. The company receives profit from the marketing of its products for various cancer types for which gemcitabine HCL has been approved.

Product Portfolio:

Gemcitabine HCL:

Gemcitabine HCL is an oncology product for various cancer types. It is FDA approved for the treatment of breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, and bladder cancer. In addition, it has been studied for its cytotoxic effect in various types of tumour treatment, including esophageal cancer.

The global Gemcitabine HCL market report would provide access to approximately 55+ market data tables, 50+ figures, and in the range of 250 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Application
  • 3.2. Market snippet By End User
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in geriatric population
      • 4.1.1.2. Increase in cancer diseases
    • 4.1.2. Restraints:
    • 4.1.3. Side effects of Gemcitabine HCL
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Pancreas Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-small Cell Lung Cancer
  • 7.4. Bladder Cancer
  • 7.5. Soft-Tissue Sarcoma
  • 7.6. Metastatic Breast Cancer
  • 7.7. Ovarian Cancer

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Homecare
  • 8.4. Specialty Centers
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Eli Lilly and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Teva Pharmaceutical Industries Ltd.
  • 12.3. Accord-UK Ltd.
  • 12.4. Pfizer, Inc.
  • 12.5. Mylan N.V.
  • 12.6. Sun Pharmaceutical Industries Ltd.
  • 12.7. Fresenius Kabi AG
  • 12.8. Dr. Reddy's Laboratories Ltd.
  • 12.9. Ingenus Pharmaceuticals
  • 12.10. NuCana Biomed's

LIST NOT EXHAUSTIVE

13. Global Gemcitabine HCL Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us